Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 in active psoriatic arthritis
2018-004293-10Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in psoriatic arthritis (PsA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR20 response. Started Apr 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-004293-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004293-10.